IMTX
Immatics N.V. trades as IMTX and has a market capitalization of $1.19 B, making it the #2511 largest US-listed company by market value. This page tracks Immatics N.V. through 220 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| 6-K | - | 2026-05-12 |
| 6-K | - | 2026-04-21 |
| 6-K | - | 2026-04-17 |
| New insider ownership | 3 | 2026-03-18 |
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting | Immatics N.V.
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer | Immatics N.V.
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting | Immatics N.V.
Immatics Announces First Quarter 2026 Financial Results and Business Update | Immatics N.V.
The largest companies sharing Immatics N.V.'s SEC industry classification (biological products, (no diagnostic substances)).
Immatics N.V. (IMTX) has a market capitalization of $1.19 B as of 2026-06-10, ranking #2511 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting | Immatics N.V.